A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Phase 2 Completed 168 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.

Timeline

Start: 2011-04
Primary completion: 2013-09
Completion: 2014-05

Publications

Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016 Dec;27(12):2196-2203. doi: 10.1093/annonc/mdw423. Epub 2016 Oct 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ramucirumab	Monoclonal antibody	8 mg/kg	Intravenous
Background	Leucovorin	Small molecule	400 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Background	fluorouracil	Small molecule	400 mg/m2	Intravenous
Background	fluorouracil	Small molecule	2400 mg/m2	Intravenous

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Summary

Timeline

Publications

Drugs

Indications